Domestic MedTech Firms Accelerate BCI Push: Multiple Companies File for IPOs and Secure Funding in April 2026

　　【Pharmaceutical Network Industry DynamicsIn April 2026, the layout of Chinese medical device companies in the brain-computer interface field significantly accelerated, with a large number of companies making clear moves in technology development, capital operations, and commercial implementation.
 

Recently, on April 27, Sirrem, a brain-computer interface rehabilitation company, announced that it has completed tens of millions in financing. This round of financing will be used to improve the layout of the brain-computer interface product line, accelerate the clinical registration and transformation of products, establish large-scale production lines, and expand channels for market expansion both domestically and internationally.
 

Data shows that Sirrem focuses on invasive brain-computer interfaces, non-invasive brain-computer interfaces, and closed-loop brain-computer interfaces. Its core product is an intelligent flexible hand function rehabilitation device.Robot, which enables precise force control, supports bidirectional active training, and is equipped with an AI evaluation system that can generate personalized plans.
 

On April 26, Shanghai Jinnao Medical Technology Co., Ltd. announced the completion of an angel round of financing worth tens of millions. The funds from this round will be mainly used for the development and clinical validation of high-density ultra-micro array electrode systems, a Class III medical device, to accelerate its progress toward medical device registration and market launch.
 

It is reported that Jinnao Technology, incubated by the National Engineering Research Center for Biochip Shanghai, is an innovative enterprise in China focusing on invasive brain-computer interfaces and a representative enterprise in China with ultra-micro array as its core technical route. Its core product, "High-Density Ultra-Micro Array Electrode System," adopts a "three-stage design" with excellent effectiveness and safety. In addition, the company also provides full-stack technical services for fundamental brain science research.
 

On April 18, the Henan Province Brain-Computer Interface Rehabilitation Equipment Technology Innovation Center, led by Xiangyu Medical, was officially inaugurated in Anyang. This tripartite collaboration to establish the Brain-Computer Interface Rehabilitation Equipment Technology Innovation Center will fully integrate resources from multiple parties to achieve complementary strengths and coordinated efforts, creating a model of industry-university-research integration involving "enterprises + universities + tertiary hospitals." After the center begins formal operations, it will focus on key core technological breakthroughs in high-precision decoding of EEG signals and multi-modal human-computer interaction, accelerating the transition of brain-computer interface rehabilitation technology from laboratory research to clinical application, benefiting more patients.
 

Subsequently, from April 24 to 26, Xiangyu Healthcare showcased cutting-edge achievements in areas such as brain-computer interface and AI intelligent rehabilitation at the Healthy China Rehabilitation Forum and China Intelligent Rehabilitation Industry Expo. Among these, the brain-computer interface product series became the highlight, with devices like upper and lower limb active-passive rehabilitation training instruments and swallowing nerve and muscle electrical stimulation instruments enabling active rehabilitation training through precise EEG signal analysis, achieving breakthroughs over traditional passive rehabilitation limitations.
 

On April 9, Aipeng Medical and Changchun Jinsai Pharmaceuticals officially signed a strategic cooperation framework agreement. The two parties will engage in in-depth cooperation to advance the application and promotion of brain-computer interface technology in pediatric ADHD and other brain health fields, jointly exploring innovative approaches for children's brain health services.
 

Among them, Jin Sai Pharmaceuticals will focus on the ADHD treatment scenario, relying on years of accumulated expert resources, medical networks, and market promotion capabilities in the pediatric field. They aim to accelerate the application of brain-computer interface-related technologies in the entire process, including screening, diagnosis and treatment, follow-up, and home management, gradually forming a standardized and replicable comprehensive solution.
 

　　……
 

The industry believes that the intensive moves in April indicate that China's brain-computer interface industry has transitioned from the "technology validation" phase to the "clinical practical application" stage. Meanwhile, industrial capital continues to flow in. In the future, companies that can convert clinical data into product advantages and establish a sustainable commercial ecosystem are expected to achieve significant success.
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.